BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Threshold Pharmaceuticals, Inc. 

170 Harbor Way
Suite 300
South San Francisco  California  94080-6108  U.S.A.
Phone: 650-474-8200 Fax: 650-474-2529


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Pharmaceutical






 Company News
Threshold Pharmaceuticals, Inc. (THLD) Announces Presentation And Webcast At The Jefferies and Co. 2015 Healthcare Conference 5/27/2015 10:34:49 AM
Threshold Pharmaceuticals, Inc. (THLD) Announces Clinical Update On Evofosfamide In Relapsed/Refractory Multiple Myeloma To Be Presented At ASCO 2015 5/14/2015 1:08:07 PM
Threshold Pharmaceuticals, Inc. (THLD)' Partner Merck KGaA (MKGAF.PK), Darmstadt, Germany, Receives FDA Fast Track Designation For Evofosfamide For The Treatment Of Patients Living With Advanced Pancreatic Cancer 5/12/2015 9:56:48 AM
Threshold Pharmaceuticals, Inc. (THLD) Reports First Quarter 2015 Financial And Operational Results 4/30/2015 8:34:32 AM
Threshold Pharmaceuticals, Inc. (THLD) Reports Preclinical Data Suggesting That TH-4000 May Overcome Resistance To Conventional EGFR Tyrosine Kinase Inhibitors 4/23/2015 11:45:48 AM
Threshold Pharmaceuticals, Inc. (THLD) To Host Analyst And Investor Day On April 24 In New York City 4/17/2015 10:51:00 AM
Threshold Pharmaceuticals, Inc. (THLD) To Present Data Supporting Planned Phase 2 Trials Of TH-4000, A Hypoxia-Activated, Irreversible EGFR Tyrosine Kinase Inhibitor 3/19/2015 11:33:56 AM
Threshold Pharmaceuticals, Inc. (THLD) Reports Fourth Quarter And Year End 2014 Financial And Operational Results 3/3/2015 9:57:58 AM
Threshold Pharmaceuticals, Inc. (THLD) Announces Presentation And Webcast At The 2015 Cowen and Company Health Care Conference 2/24/2015 12:37:44 PM
Threshold Pharmaceuticals, Inc. (THLD) Announces Pricing Of $30 Million Offering Of Common Stock And Warrants 2/13/2015 10:37:34 AM
12345678910...